Literature DB >> 20049626

Regulating A549 cells growth by ASO inhibiting miRNA expression.

Ping-Yu Wang1, You-Jie Li, Shuai Zhang, Zun-Ling Li, Zhen Yue, Ning Xie, Shu-Yang Xie.   

Abstract

MicroRNAs (miRNAs) have a profound impact on cell processes, including proliferation, apoptosis, and stress responses. We aimed to explore the role of antisense oligonucleotide (ASO) to induce proliferation or apoptosis of A549 cancer cells by inhibiting the expression of miRNAs. After A549/HBE/293T cells were treated with ASO, cells proliferation/apoptosis, and their relevant oncogenes/tumor suppressor genes were detected by light and electron microscopy, real-time PCR, enzyme-linked immunosorbent assay, etc. The results showed that ASO could inhibit the expression of miRNAs effectively. miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs. Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53, respectively. After A549 cells treated with ASO for 24 h and different concentrations of anti-cancer drug (cisplatin or demethylcantharidin) were added into culture medium, the results indicated the percentage of alive cells in group treated with both ASO-106 (or ASO-150) and anti-cancer drug was lower than that in group treated with ASO, or anti-cancer drug, or both ASO-16 (or ASO-34a) and anti-cancer drug. In conclusion, ASO (specific to oncogenic miRNAs) could induce A549 cells apoptosis by inhibiting oncogenic miRNAs, and could increase chemotherapy sensitivity of A549 cells to anti-cancer drug, which holds great promise to lung cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049626     DOI: 10.1007/s11010-009-0380-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma.

Authors:  Markus Metzler; Monika Wilda; Kerstin Busch; Susanne Viehmann; Arndt Borkhardt
Journal:  Genes Chromosomes Cancer       Date:  2004-02       Impact factor: 5.006

2.  Secalonic acid D; A cytotoxic constituent from marine lichen-derived fungus Gliocladium sp. T31.

Authors:  Hong Ren; Li Tian; Qianqun Gu; Weiming Zhu
Journal:  Arch Pharm Res       Date:  2006-01       Impact factor: 4.946

Review 3.  Molecular mechanisms of antisense drugs: RNase H.

Authors:  S T Crooke
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1998-04

4.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

5.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

6.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 7.  MiRNAs and cancer.

Authors:  Rosa Visone; Carlo M Croce
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

Review 8.  Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

Authors:  A W Tong; J Nemunaitis
Journal:  Cancer Gene Ther       Date:  2008-03-28       Impact factor: 5.987

9.  Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.

Authors:  Mitsushige Nakao; Shigeo Horiike; Yoko Fukushima-Nakase; Motohiro Nishimura; Yasuko Fujita; Masafumi Taniwaki; Tsukasa Okuda
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

10.  miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Julia Mohr; Eric Eldering; Arnon P Kater; Andreas Bühler; Dirk Kienle; Dirk Winkler; Jan Dürig; Marinus H J van Oers; Daniel Mertens; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

View more
  22 in total

1.  Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia.

Authors:  Anatoliy I Masyuk; Bing Q Huang; Christopher J Ward; Sergio A Gradilone; Jesus M Banales; Tatyana V Masyuk; Brynn Radtke; Patrick L Splinter; Nicholas F LaRusso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-15       Impact factor: 4.052

2.  Role of microRNA-150 in solid tumors.

Authors:  Fang Wang; Xiubao Ren; Xinwei Zhang
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

Review 3.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

Review 4.  MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Authors:  Ji Qi; David Mu
Journal:  Front Med       Date:  2012-04-18       Impact factor: 4.592

5.  Engineering a customized nanodrug delivery system at the cellular level for targeted cancer therapy.

Authors:  Jin Li; Liping Qiu; Sitao Xie; Jing Zhang; Liqin Zhang; Honglin Liu; Juan Li; Xiaobing Zhang; Weihong Tan
Journal:  Sci China Chem       Date:  2018-01-11       Impact factor: 9.445

6.  Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth.

Authors:  Yan-Xia Zhang; Zhen Yue; Ping-Yu Wang; You-Jie Li; Jia-Xuan Xin; Min Pang; Qing-Yin Zheng; Shu-Yang Xie
Journal:  Biomed Pharmacother       Date:  2012-12-28       Impact factor: 6.529

7.  MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer.

Authors:  Lauren MacDonagh; Michael F Gallagher; Brendan Ffrench; Claudia Gasch; Steven G Gray; Marie Reidy; Siobhan Nicholson; Niamh Leonard; Ronan Ryan; Vincent Young; John J O'Leary; Sinead Cuffe; Stephen P Finn; Kenneth J O'Byrne; Martin P Barr
Journal:  Transl Lung Cancer Res       Date:  2021-04

Review 8.  MicroRNA: Crucial modulator in purinergic signalling involved diseases.

Authors:  Jing Guo; Peng Yang; Yi-Fan Li; Jin-Fan Tang; Zhao-Xuan He; Shu-Guang Yu; Hai-Yan Yin
Journal:  Purinergic Signal       Date:  2022-02-02       Impact factor: 3.765

9.  A novel pathway of TEF regulation mediated by microRNA-125b contributes to the control of actin distribution and cell shape in fibroblasts.

Authors:  Olga Gutierrez; Maria T Berciano; Miguel Lafarga; Jose L Fernandez-Luna
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

10.  Alterations of serum levels of BDNF-related miRNAs in patients with depression.

Authors:  You-Jie Li; Mei Xu; Zong-Hua Gao; Ya-Qi Wang; Zhen Yue; Yan-Xia Zhang; Xin-Xin Li; Can Zhang; Shu-Yang Xie; Ping-Yu Wang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.